Evaluation of new drugs: Recombinant interleukin-2

J. K. Bruton, J. M. Koeller

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Recombinant interleukin (IL)-2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range of immunologic effects. It is a true biologic response modifier in that is has no known direct antitumor activity, but mediates its cytotoxicity through activation of effector cells including T cells, natural killer cells, and lymphokine- activated killer cells. Recombinant IL-2 has demonstrated activity in patients with renal cell carcinoma and melanoma, with objective response rates of approximately 15-20%. The median duration of response in renal cell carcinoma is 23 months. Toxicity experienced with high-dose IL-2 can be significant. The most common dose-limiting toxicities are hypertension, weight gain, oliguria, respiratory insufficiency, and neurotoxicity. These effects are generally manageable and reversible on discontinuation of therapy. Administration of low-dose IL-2 has emerged as a means of substantially reducing toxicity. At least in renal cell carcinoma, it appears that the response rate to low-dose IL-2 is comparable to that with higher dosages.

Original languageEnglish (US)
Pages (from-to)635-656
Number of pages22
JournalPharmacotherapy
Volume14
Issue number6 I
StatePublished - 1994

Fingerprint

Drug Evaluation
Interleukin-2
Renal Cell Carcinoma
Oliguria
Lymphokine-Activated Killer Cells
Natural Killer Cells
Respiratory Insufficiency
Weight Gain
Melanoma
Lymphocytes
Hypertension
T-Lymphocytes
Proteins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bruton, J. K., & Koeller, J. M. (1994). Evaluation of new drugs: Recombinant interleukin-2. Pharmacotherapy, 14(6 I), 635-656.

Evaluation of new drugs : Recombinant interleukin-2. / Bruton, J. K.; Koeller, J. M.

In: Pharmacotherapy, Vol. 14, No. 6 I, 1994, p. 635-656.

Research output: Contribution to journalArticle

Bruton, JK & Koeller, JM 1994, 'Evaluation of new drugs: Recombinant interleukin-2', Pharmacotherapy, vol. 14, no. 6 I, pp. 635-656.
Bruton JK, Koeller JM. Evaluation of new drugs: Recombinant interleukin-2. Pharmacotherapy. 1994;14(6 I):635-656.
Bruton, J. K. ; Koeller, J. M. / Evaluation of new drugs : Recombinant interleukin-2. In: Pharmacotherapy. 1994 ; Vol. 14, No. 6 I. pp. 635-656.
@article{174ca72c51d64bfaa711ca6c1827afe8,
title = "Evaluation of new drugs: Recombinant interleukin-2",
abstract = "Recombinant interleukin (IL)-2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range of immunologic effects. It is a true biologic response modifier in that is has no known direct antitumor activity, but mediates its cytotoxicity through activation of effector cells including T cells, natural killer cells, and lymphokine- activated killer cells. Recombinant IL-2 has demonstrated activity in patients with renal cell carcinoma and melanoma, with objective response rates of approximately 15-20{\%}. The median duration of response in renal cell carcinoma is 23 months. Toxicity experienced with high-dose IL-2 can be significant. The most common dose-limiting toxicities are hypertension, weight gain, oliguria, respiratory insufficiency, and neurotoxicity. These effects are generally manageable and reversible on discontinuation of therapy. Administration of low-dose IL-2 has emerged as a means of substantially reducing toxicity. At least in renal cell carcinoma, it appears that the response rate to low-dose IL-2 is comparable to that with higher dosages.",
author = "Bruton, {J. K.} and Koeller, {J. M.}",
year = "1994",
language = "English (US)",
volume = "14",
pages = "635--656",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6 I",

}

TY - JOUR

T1 - Evaluation of new drugs

T2 - Recombinant interleukin-2

AU - Bruton, J. K.

AU - Koeller, J. M.

PY - 1994

Y1 - 1994

N2 - Recombinant interleukin (IL)-2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range of immunologic effects. It is a true biologic response modifier in that is has no known direct antitumor activity, but mediates its cytotoxicity through activation of effector cells including T cells, natural killer cells, and lymphokine- activated killer cells. Recombinant IL-2 has demonstrated activity in patients with renal cell carcinoma and melanoma, with objective response rates of approximately 15-20%. The median duration of response in renal cell carcinoma is 23 months. Toxicity experienced with high-dose IL-2 can be significant. The most common dose-limiting toxicities are hypertension, weight gain, oliguria, respiratory insufficiency, and neurotoxicity. These effects are generally manageable and reversible on discontinuation of therapy. Administration of low-dose IL-2 has emerged as a means of substantially reducing toxicity. At least in renal cell carcinoma, it appears that the response rate to low-dose IL-2 is comparable to that with higher dosages.

AB - Recombinant interleukin (IL)-2 is a newly approved immunoregulatory protein produced by lymphocytes that exhibits a wide range of immunologic effects. It is a true biologic response modifier in that is has no known direct antitumor activity, but mediates its cytotoxicity through activation of effector cells including T cells, natural killer cells, and lymphokine- activated killer cells. Recombinant IL-2 has demonstrated activity in patients with renal cell carcinoma and melanoma, with objective response rates of approximately 15-20%. The median duration of response in renal cell carcinoma is 23 months. Toxicity experienced with high-dose IL-2 can be significant. The most common dose-limiting toxicities are hypertension, weight gain, oliguria, respiratory insufficiency, and neurotoxicity. These effects are generally manageable and reversible on discontinuation of therapy. Administration of low-dose IL-2 has emerged as a means of substantially reducing toxicity. At least in renal cell carcinoma, it appears that the response rate to low-dose IL-2 is comparable to that with higher dosages.

UR - http://www.scopus.com/inward/record.url?scp=0028534735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028534735&partnerID=8YFLogxK

M3 - Article

C2 - 7885967

AN - SCOPUS:0028534735

VL - 14

SP - 635

EP - 656

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6 I

ER -